Abaloparatide
PTHrP analog for osteoporosis treatment. Selective PTH1 receptor agonist with enhanced bone anabolic effects and reduced hypercalcemia risk compared to teriparatide.
Abaloparatide is a synthetic analog of human parathyroid hormone-related protein (PTHrP) consisting of the N-terminal 34 amino acids with specific modifications. It is approved for the treatment of osteoporosis in postmenopausal women at high risk of fracture, and in men with primary or hypogonadal osteoporosis. Compared to teriparatide, abaloparatide demonstrates more transient receptor activation with less sustained cAMP signaling, potentially offering an improved bone formation-to-resorption ratio and a favorable cardiovascular safety profile.
| Parameter | Specification |
| CAS | 247062-33-5 |
| Molecular Formula | C₁₇₄H₃₀₀N₅₆O₄₉ |
| Molecular Weight | 3960.59 g/mol |
| Category | Bone Health |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | Postmenopausal osteoporosis, bone density enhancement, fracture prevention |
| CAS | 247062-33-5 |
|---|---|
| Applications | Glucocorticoid-induced Osteoporosis, Postmenopausal Osteoporosis (high fracture risk) |
Related products
-
Liraglutide
CAS: 204656-20-2Applications: cardiovascular risk reduction, GLP-1, obesity management -
Glucagon HCl
CAS: 16941-32-5Applications: Diabetic Emergency, Glycogenolysis, Hypoglycemia Rescue -
Retatrutide
CAS: 2381089-83-2Applications: Refractory diabetes, Severe obesity, Triple agonist, weight management -
Survodutide
CAS: 2805997-46-8Applications: Liver Fat, NASH, obesity management, Type 2 diabetes